A Convenient New and Efficient Commercial Synthetic Route for Dasatinib (Sprycel®)

Authors: Garbapu Suresh, Ratnakaram Venkata Nadh, Navuluri Srinivasu, Durgaprasad Yennity

A new and efficient synthetic route for dual-Src/Abl kinase inhibitor dasatinib (Sprycel®), an anticancer drug, is described. This commercially viable process yields dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity >99.80% over four stages.

Comments: 12 Pages. OK

Download: PDF

Submission history

[v1] 2019-05-19 02:59:03

Unique-IP document downloads: 17 times is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. will not be responsible for any consequences of actions that result from any form of use of any documents on this website.

Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.

comments powered by Disqus